Cytokine release syndrome.
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS. · 2018
Read Cytokine release syndrome. by Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6003181.txt.
Description
Shimabukuro-Vornhagen and co-authors review cytokine release syndrome, a dangerous side effect of modern cancer immunotherapy. Their review appeared in the Journal for Immunotherapy of Cancer. Potent new treatments have transformed cancer care this decade. Checkpoint drugs and engineered T cells work remarkably well. Yet they can trigger a whole-body inflammatory storm. That storm can prove fatal if missed. The term dates to an early anti-T-cell antibody drug.
The review covers how the syndrome develops mechanistically. Risk factors, symptoms, and look-alike conditions are laid out. Prognostic signs that warn of severe courses are covered. Practical guidance for managing patients follows the evidence.
Catalog record
| CREATOR | Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |